Study of the Fimasartan effects on cardiovascular events and metabolic syndrome in patients with hypertension

Trial Profile

Study of the Fimasartan effects on cardiovascular events and metabolic syndrome in patients with hypertension

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Fimasartan (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions
  • Acronyms K-MetS
  • Sponsors Boryung
  • Most Recent Events

    • 10 Nov 2016 Status changed from recruiting to completed, according to the Korean Clinical Trials Register record.
    • 29 Sep 2016 Results (n=777) assessing short-term changes of metabolic syndrome and blood pressure in hypertensive women, presented at the 26th Scientific Meeting of the International Society of Hypertension
    • 29 Sep 2016 Efficacy and safety 1-year follow-up results (n=2363) of elderly patients were presented at the 26th Scientific Meeting of the International Society of Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top